Clinical trials located in


Barcelona city is located in Spain. Currently, 20 clinical trials are being conducted in this city.

Barcelona, Spain’s second-largest city, is renowned for its rich cultural heritage and architectural marvels. Founded as a Roman city, it boasts a unique blend of Gothic and Modernist architecture, epitomized by Antoni Gaudí’s Sagrada Família. The city is also famous for its vibrant street life, with the bustling La Rambla offering a snapshot of local life. Barcelona’s beaches, among the best in the world, add to its charm. It’s a hub of art and cuisine, home to numerous museums and a thriving culinary scene. The city also has a deep-rooted sports culture, highlighted by the iconic FC Barcelona.

  • CT-EU-00121786

    Gene therapy safety and efficacy study for adults with Gaucher Disease Type 1

    This clinical trial is a groundbreaking study aimed at patients with Gaucher Disease Type 1. It is the first of its kind to explore the use of a gene therapy called FLT201. The study is open-label, meaning both the researchers and participants know what treatment is being administered. The primary goals are to assess the safety, tolerability, and efficacy of FLT201 in adult patients.

    The trial will investigate how different doses of FLT201 affect the levels of an enzyme called glucocerebrosidase (GCase). This enzyme is crucial for breaking down certain substances in the body, and its deficiency leads to the symptoms of Gaucher Disease. By increasing GCase activity and concentration, the study aims to see if FLT201 can improve the clinical symptoms of the disease by reducing and preventing the buildup of harmful substances in cells.

    One of the key aspects being monitored is the incidence of treatment-emergent adverse events, which includes any side effects that occur after the treatment is administered. These adverse events will be categorized as mild, moderate, or severe and will be tracked from the first day of dosing through the final follow-up visit at Week 38.

  • Study comparing Giredestrant and Fulvestrant with CDK4/6 Inhibitors for advanced breast cancer

    This study focuses on a type of advanced breast cancer known as Estrogen Receptor-Positive (ER+), HER2-Negative breast cancer. This kind of cancer is driven by hormones and does not have high levels of the HER2 protein. The study aims to evaluate the effectiveness and safety of a new drug called Giredestrant compared to an existing drug called Fulvestrant. Both drugs will be combined with one of three medicines that inhibit proteins in cancer cells called CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib).

    In this study, participants will be randomly assigned to one of two groups. One group will receive Giredestrant and the other will receive Fulvestrant. Both groups will also receive one of the CDK4/6 inhibitors chosen by their doctor. These combinations are being tested to see which works better to stop the cancer from growing or spreading.

    The drugs involved include Giredestrant (RO7197597, RG6171, GDC-9545), Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, and LHRH Agonist (for pre/perimenopausal women and men).

    The goal is to find out if Giredestrant can provide better results and fewer side effects compared to Fulvestrant when both are combined with one of the CDK4/6 inhibitors. The study may involve regular tests and assessments to monitor the cancer’s progress and the patient’s response to the treatment.

    Participants will continue to receive the study drugs as long as they are benefiting from them and not experiencing unacceptable side effects. The study involves close monitoring to ensure the safety and well-being of all participants throughout the treatment period.

    • LHRH Agonist
    • Abemaciclib
    • Giredestrant
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • Safety and efficacy study of BA3021 for patients with lung cancer, breast cancer, melanoma, or head and neck cancer

    This clinical trial targets various types of cancer such as Non-Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Melanoma, and Head and Neck Cancer. The therapy being assessed involves BA3021 (CAB-ROR2-ADC), a specialized drug designed to target cancer cells. Another drug, a PD-1 inhibitor, will also be used in one part of the study.

    The primary goal of this study is to evaluate the safety and effectiveness of BA3021, alone or in combination with a PD-1 inhibitor, in treating advanced solid tumors.

    This trial will be carried out in two phases:
    Phase 1 will focus on understanding the appropriate dose and its safety, while
    Phase 2 will evaluate how well the drug works alone or together with the PD-1 inhibitor.

    Participants will receive either BA3021 alone or BA3021 in combination with the PD-1 inhibitor. They will be monitored closely throughout the study to track their health and the drug’s effects on their cancer.

  • CT-EU-00068410

    A study of the treatment of advanced breast cancer with Giredestrant and the drug combination Phesgo

    The study is aimed at patients with locally advanced or metastatic breast cancer that is HER2-positive and ER-positive. HER2 and ER are receptors that can influence the growth of cancer cells. The aim of this study is to evaluate the effectiveness and safety of the combination of giredestrant and Phesgo compared with Phesgo alone after a run-in phase with Phaesgo and taxane-based chemotherapy.

    Phesgo is a combination containing pertuzumab, trastuzumab and hyaluronidase, administered subcutaneously every three weeks. Giredestrant is a capsule taken orally every day. Taxane chemotherapy may include drugs such as Docetaxel and Paclitaxel, which are given intravenously. The aim of the study is to compare how well these drug combinations work in preventing disease progression and improving patient survival.

    • hyaluronidase
    • Giredestrant
    • Pertuzumab
    • Trastuzumab
    • Paclitaxel
    • Docetaxel
  • Study of Aplitabart alone or with other treatments in patients with various cancers

    This clinical trial concerns various cancers including solid tumors, colorectal cancer, non-Hodgkin lymphoma, sarcoma, chondrosarcoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.

    The main focus of this study is the investigation of a drug called aplitabart (IGM-8444). This drug will be tested alone and in combination with other medications, which include FOLFIRI (a combination chemotherapy regimen), bevacizumab (a targeted therapy also known as Avastin), birinapant (an investigational drug), venetoclax (a targeted therapy also known as Venclexta), docetaxel (a chemotherapy drug also known as Taxotere or Docefrez), gemcitabine (a chemotherapy drug also known as Gemzar), and azacitidine (a chemotherapy drug also known as VIDAZA). The purpose of the study is to determine the safety, tolerability, and how the body processes (pharmacokinetics) aplitabart when used alone or combined with these other drugs.

    There are two main parts of the study. Phase 1a consists of two stages: Dose escalation, where participants will receive increasing doses of aplitabart to determine the safest and most effective dose, and Expansion, where more participants will receive the best dose to see how well it works alone or with other drugs. Phase 1b will focus on colorectal cancer participants. It will be an open-label, randomized study where some participants will receive a combination of aplitabart, FOLFIRI, and bevacizumab, while others will receive only FOLFIRI and bevacizumab.

    All medications will be given intravenously (through a vein). Different tumor types will be included, such as various solid tumors, colorectal cancers, certain types of leukemia, and lymphomas.

    • Aplitabart (IGM-8444)
    • azacitidine
    • Bevacizumab (and approved biosimilars)
    • Birinapant
    • Gemcitabine
    • Venetoclax
    • Docetaxel
  • Study of the safety and effectiveness of GLSI-100 in patients with HER2-positive breast cancer

    The study concerns the treatment of patients with HER2/neu-positive breast cancer. Treatment will include GLSI-100 immunotherapy and comparison to placebo. GLSI-100 consists of GP2 peptide and GM-CSF, protein substances that are designed to strengthen the body’s immune response, i.e. natural protection against diseases.

    The aim of this study is to determine how effective and safe GLSI-100 therapy is compared to placebo in preventing breast cancer recurrence after standard treatment. The study is aimed at people at high risk of disease recurrence who have completed both preoperative and postoperative therapy based on trastuzumab, a drug used to treat breast cancer.

    The study will assess invasive breast cancer-free survival (i.e. the time from the first dose of the drug to the moment of disease recurrence or death from any cause), invasive disease-free survival (i.e. the time from the first dose of the drug to the moment of any disease recurrence or new cancer), remote disease (i.e. time until disease recurrence in a place other than the breast or death).

    The study also includes an assessment of the participants’ quality of life both at the beginning and over the next 36 months, as well as an analysis of the body’s immune response to treatment.

  • CT-EU-00068643

    Study of the effects and safety of Inavolisib and Fulvestrant compared with Alpelisib and Fulvestrant in patients with advanced breast cancer

    The clinical trial is for breast cancer. Its aim is to evaluate the effectiveness and safety of the drug combination inavolisib and fulvestrant compared with the drug combination alpelisib and fulvestrant.

    It is aimed at patients with locally advanced or metastatic breast cancer. All patients who will participate in the study have previously undergone therapy based on cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and hormonal therapy. Study participants’ breast cancer must be hormone receptor positive (HR+), human epidermal growth factor receptor type 2 negative (HER2-), and must have a PIK3CA gene mutation.

    The aim of the study is to compare which drug combination – inavolisib and fulvestrant or alpelisib and fulvestrant – is more effective in the treatment of this type of breast cancer. This study also tries to assess what the side effects of both therapies are.

    Inavolisib and fulvestrant treatment involves administering inavolisib tablets once a day and fulvestrant injections at the beginning and during treatment cycles. An alternative treatment, i.e. alpelisib with fulvestrant, also involves daily use of alpelisib tablets and fulvestrant injections according to planned cycles.

    • Alpelisib
    • Fulvestrant
    • Inavolisib
  • Study of INBRX-109 for patients with unresectable or metastatic conventional chondrosarcoma

    Conventional chondrosarcoma is a type of cancer that affects the bones. This clinical trial focuses on evaluating a new treatment for patients with unresectable (inoperable) or metastatic (spread to other parts of the body) conventional chondrosarcoma. The therapy being tested is called INBRX-109. INBRX-109 is an experimental drug, specifically a humanized antibody that targets a protein called death receptor 5 (DR5). The study aims to determine whether INBRX-109 can help patients who have this type of bone cancer.

    In this study, participants will be randomly assigned to one of two groups: one group will receive INBRX-109, and the other will receive a placebo. Neither the participants nor the researchers will know who is receiving the actual drug and who is receiving the placebo. This is known as a double-blind study. Participants will receive their assigned treatment through an intravenous infusion every three weeks. If the disease progresses, those in the placebo group will be allowed to switch to the INBRX-109 treatment.

    The primary goal of the study is to see how well INBRX-109 works in preventing the cancer from getting worse. The study will also look at overall survival rates, how long any responses to the treatment last, and the quality of life of the participants during the study. Safety and tolerability of INBRX-109 will also be evaluated by monitoring for any side effects. Participants will have regular visits and tests to check on their condition and the effects of the treatment. This clinical trial offers a potential new treatment option for patients with difficult-to-treat chondrosarcoma, aiming to improve their outcomes and quality of life.

    • INBRX-109
    • placebo
  • Study on the effectiveness and safety of DMX-200 for FSGS patients using ARB

    Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease where some parts of the kidneys become scarred, leading to kidney damage and protein loss in urine. This study involves a therapy using an experimental drug named DMX-200 (also known as repagermanium), which, when taken with a type of medication called an Angiotensin II Receptor Blocker (ARB), aims to halt the inflammation that contributes to chronic kidney disease.

    The study is designed to assess how well DMX-200 works and how safe it is in treating people with FSGS. It will compare the effects of DMX-200 with a placebo over a period of 104 weeks (about 2 years). Patients will be given either DMX-200 in capsule form to take twice daily or a placebo. Given the rarity of FSGS, the study will include both adults and adolescents aged 12 to 17 years.

    The study will start with a screening period to ensure all necessary assessments are completed. This will be followed by the main treatment phase, lasting 104 weeks. After this, there will be a 4-week follow-up period without treatment to observe any changes. Patients who complete this double-blind period and might benefit from continued treatment will enter an open-label extension phase. During this phase, participants will receive DMX-200 for an additional 2 years, also followed by a 4-week off-treatment period for further observation.

    The goal is to determine the effectiveness and long-term safety of DMX-200 for treating FSGS. The study aims to improve understanding and develop new treatments for this challenging kidney condition.

    • DMX-200
    • placebo
  • Testing BI 764198 for Kidney Disease (FSGS): A 4-Month Study

    This study is focused on individuals with a kind of kidney disease called Focal Segmental Glomerulosclerosis (FSGS). The purpose is to see if a drug named BI 764198 can improve kidney health for people with FSGS. There will be three different doses of BI 764198 tested in the study.

    Participants in the study will be divided into four groups randomly. Three groups will receive different doses of BI 764198, and one group will receive a placebo. The study will last about four months. For approximately three months, participants will take a BI 764198 capsule or placebo capsule daily.

    Participants will visit the study site around ten times. It is possible to participate from home, in which case a research nurse will visit for the study visits. Kidney health will be checked by analyzing urine samples that participants collect at home. The results will be compared between the different groups at the end of the study. Throughout the study, doctors will also regularly monitor the general health of participants.

    • BI 764198
    • placebo
  • Studying the safety of a new medicine in treating Primary biliary cholangitis (PBC)

    The study is aimed at patients suffering from primary biliary cholangitis (PBC), a disease causing inflammation and narrowing of the bile ducts. The therapy involves the administration of the drug A3907, also known as Ritivixibat.

    The main goal of the study is to evaluate how safe and well-tolerated A3907 is in individuals with PBC. Additionally, doctors will examine how participants’ bodies respond to the drug and what changes occur during treatment.

    Adults aged 18 to 75 with clinical symptoms of PBC for at least six months can participate. The study includes various dosing groups of A3907 to understand which dose is most effective and safe.

    An important aspect of the study is that participants must be clinically stable for at least three months prior to its commencement. Women of childbearing age must use appropriate contraceptive methods, and all participants must be willing to sign informed consent.

    The study does not include individuals with other chronic liver diseases, including cirrhosis, or those who have had liver transplants or other internal organ surgeries in the past.

  • Study on the use of Volixibat for the treatment of pruritus in patients with primary cholangitis (PBC)

    The purpose of this clinical trial is to evaluate the efficacy and safety of an investigational drug called volixibat in patients with pruritus caused by primary cholangitis. The study aims to understand how volixibat affects the treatment of pruritus associated with this disease and to evaluate its possible effect on disease progression.

    Study participants will be randomly assigned to a group receiving volixibat or placebo. Volixibat will be administered as oral capsules twice daily. The main goal of the study is to measure the average change in daily pruritus scores using a special Adult Itch Reported Outcome (Adult ItchRO) questionnaire. Adult ItchRO is an 11-point scale for assessing pruritus severity, where 0 means no pruritus and 10 means the worst possible pruritus. The study will run from baseline to week 28.

    • Volixibat
    • Placebo
  • Testing Tislelizumab and Spartalizumab for Various Cancers with High PD1 Levels

    This study focuses on the treatment of various types of cancer, including colorectal cancer, melanoma, anal carcinoma, mesothelioma, triple-negative breast cancer, lung adenocarcinoma, cholangiocarcinoma, cervical carcinoma, kidney clear cell carcinoma, stomach adenocarcinoma, esophageal adenocarcinoma, uterine adenocarcinoma, head and neck squamous cell carcinoma, sarcoma, lung squamous cell carcinoma, urothelial carcinoma, thyroid carcinoma, hepatocellular carcinoma, uveal melanoma, HER2-positive breast cancer, pancreatic adenocarcinoma, squamous esophageal carcinoma, epithelial ovarian cancer, uterine carcinosarcoma, small cell lung cancer, hormone receptor positive/HER2-negative breast cancer, lung adenocarcinoma with EGFR mutation or ALK translocation, colorectal adenocarcinoma, prostate adenocarcinoma, carcinoma of unknown primary, and other histologies.

    The therapy involves two drugs: Spartalizumab and Tislelizumab. Spartalizumab is administered at a dose of 400 mg intravenously every 28 days, while Tislelizumab is administered at a dose of 300mg intravenously every 28 days.

    The purpose of this study is to evaluate the effectiveness of these drugs in patients with tumors that express high levels of a protein called PD1 or lower levels in which PD1/PD-L1 inhibitors have been previously established to be effective. PD1 is a protein found on the surface of cells that helps keep the body’s immune responses in check and blocks cancer-fighting immune cells.

    The study is divided into three groups, called cohorts. Patients will first sign a consent form to allow a molecular test to determine the PD1 levels of their tumor. Patients with high PD1-expressing tumors will be placed into cohort 1 or cohort 3. Those with low PD1-expressing tumors, where the effectiveness of similar treatments has been previously established, will be placed into cohort 2.

    – Cohort 1 will receive Spartalizumab as monotherapy (single drug treatment).
    – Cohort 2, consisting of patients with PD1-low tumors, will also receive Spartalizumab as monotherapy.
    – Cohort 3 will receive Tislelizumab as monotherapy.

    Frequent evaluations will be conducted to monitor the patient’s response to the treatment. Participants will receive the drugs intravenously (through a vein) every 28 days and will be closely observed for any improvements or potential side effects.

    • Spartalizumab
    • Tislelizumab
  • Study of KFA115 alone and with pembrolizumab for Advanced Cancers

    This study focuses on a range of advanced cancers, including non-small-cell lung cancer, cutaneous melanoma (a type of skin cancer), renal cell carcinoma (kidney cancer), ovarian epithelial carcinoma, nasopharyngeal carcinoma (cancer in the upper part of the throat), thymic carcinoma (thymus gland cancer), anal cancer, mesothelioma (cancer in the lining of the lungs, stomach, heart, or other organs), esophagogastric cancer (cancer of the esophagus and stomach), high microsatellite instability colorectal carcinoma (a type of colorectal cancer), squamous cell carcinoma of the head and neck, and triple negative breast neoplasms (a subtype of breast cancer that lacks three common receptors).

    The study evaluates the safety and effectiveness of using a new drug named KFA115 both alone and in combination with pembrolizumab, an anti-PD-1 antibody also known as Keytruda. The purpose of this study is to see how safe KFA115 is and to learn more about how well patients tolerate it, whether used alone or in combination with pembrolizumab. The study also aims to determine the best dose to recommend for future studies.

    The study will begin with a dose escalation phase to find the safest dose and understand its side effects. In this part, patients will receive increasing doses of KFA115, either by itself or combined with pembrolizumab, to identify the highest dose they can safely tolerate. Once the best dose is found, the study will enter a dose expansion phase, where more patients will be treated with this dose to see its preliminary effectiveness against cancer and further verify its safety.

    There are multiple patient groups in this study: one group will receive only KFA115, another will start with KFA115 and then add pembrolizumab after one cycle, and the last group will receive both KFA115 and pembrolizumab at the same time.

    By participating in this study, patients may contribute to the development of new cancer treatments that could benefit future patients with similar advanced cancers.

    • KFA115
    • Pembrolizumab
  • Combining immunotherapy and chemoradiotherapy for Anal Cancer treatment

    Anal carcinoma, specifically squamous cell carcinoma of the anal canal, will be the focus of this study. Patients who have not previously received treatment for this type of cancer and are candidates for combined chemotherapy and radiation treatment will participate. This study will examine the effectiveness of adding immunotherapy drugs, Atezolizumab and Tiragolumab, to standard chemoradiotherapy. These drugs help the body’s immune system recognize and attack cancer cells. The main objective is to determine if this combination can achieve a complete response, meaning the cancer completely disappears according to certain medical evaluations.

    Throughout the study, patients will first receive two cycles of Atezolizumab and Tiragolumab along with chemoradiotherapy, which includes the chemotherapy drugs Cisplatin and 5-Fluorouracil, and a specific schedule of radiation therapy. After this initial phase, they will continue with Atezolizumab and Tiragolumab for an additional 24 weeks during a consolidation phase.

    Safety, the effectiveness of treatment, patients’ quality of life, and certain molecular biomarkers in the cancer and blood will be closely monitored throughout the study. Patients can stop the treatment if there are risks of progression, serious side effects, or based on decisions made by themselves or their doctors.

    This study hopes to provide greater insight into whether combining these immunotherapy drugs with standard treatment can improve outcomes for patients with localized squamous cell carcinoma of the anal canal.

    • Atezolizumab plus Tiraglolumab
  • Study on the effectiveness and safety of Ianalumab for treating Warm Autoimmune Hemolytic Anemia

    This clinical trial is designed to evaluate the efficacy and safety of a drug called ianalumab in patients with warm autoimmune hemolytic anemia (wAIHA) who have not responded to at least one previous treatment. The study aims to determine if ianalumab can induce and maintain a durable hemoglobin response compared to a placebo.

    Participants will be randomly assigned to receive one of two different doses of ianalumab or a placebo. If a participant assigned to the placebo group does not respond to the treatment, they may be given ianalumab in an open-label manner, meaning both the participant and the doctor will know they are receiving the drug.

    The investigational treatment will be administered through an intravenous (i.v.) infusion. During the study, participants will have regular visits every other week during the treatment period and primary endpoint follow-up period. For safety monitoring, visits will occur monthly for the first 20 weeks after the last dose and then quarterly for up to two years. If a participant achieves a durable response, additional monthly visits for efficacy will continue for the first two years after the last dose, followed by quarterly visits until the loss of response or the end of the study, which could be up to 39 months after the last participant is randomized.

    The primary goal is to see if ianalumab can achieve a durable hemoglobin response, defined as a hemoglobin level of at least 10 g/dL and an increase of at least 2 g/dL from baseline for a period of at least eight consecutive weeks between weeks 9 and 25, without the need for rescue medication or prohibited treatment.

    This study offers hope for patients with wAIHA who have not found success with other treatments, providing a potential new option to manage their condition.

    • placebo
  • Study on the effectiveness and safety of M281 in adults with warm Autoimmune Hemolytic Anemia

    The study focuses on Warm Autoimmune Hemolytic Anemia (wAIHA), a condition where the immune system mistakenly destroys red blood cells. This leads to symptoms like fatigue, weakness, and jaundice (yellowing of the skin or eyes). The trial examines the effects of a therapy named M281 (Nipocalimab). The purpose of the study is to evaluate the efficacy and safety of M281. Patients participating in the study will receive either M281 or a placebo. It aims to compare improvements in health and monitor any side effects.

    The study structure is as follows:

    Double-blind period: This lasts for 24 weeks, where participants will be randomly assigned to one of three groups. One group will receive M281 every 4 weeks, alternating with a placebo every 4 weeks. Another group will receive M281 every 2 weeks, and the third group will receive a placebo every 2 weeks.

    Open-label extension period: This phase extends for 144 weeks, where all participants will receive M281, either every 2 weeks or every 4 weeks.

    Participants will be monitored for 8 weeks after the last dose to check for any ongoing effects of the treatment. The study aims to provide comprehensive information about the effectiveness and safety of M281 in treating wAIHA.

    • M281
    • placebo
  • Comparison of Olorofim and AmBisome® for Treating Invasive Aspergillosis in Patients Who Cannot Use Azole Therapy

    This study focuses on patients dealing with a serious fungal infection called Invasive Aspergillosis (IA). This infection is known to be particularly dangerous for people with weakened immune systems. Two drugs will be compared in this study: Olorofim (also known as F901318) and AmBisome® (liposomal amphotericin B). These drugs are used to treat patients who have a confirmed or suspected IA infection.

    AmBisome® is an established treatment, while Olorofim is a newer medication that works differently. This new drug aims to provide an alternative for patients who don’t respond well to existing therapies.

    The purpose of this study is to compare the effectiveness and safety of Olorofim with AmBisome®, followed by standard care according to medical guidelines. Patients will receive one of the treatments, and their response will be monitored over several months.

    Patients will start with either Olorofim or AmBisome® for a set period, then switch to the standard care recommended by their doctors. This approach allows researchers to understand how well each treatment works and what side effects might occur.

    Participation includes regular follow-ups and assessments to monitor the patient’s health, response to the medication, and any potential side effects. The ultimate goal is to find the best possible treatment for IA, improving outcomes for patients affected by this serious fungal infection.

    • AmBisome®
    • olorofim
  • Testing Gantenerumab and Drug Combinations for Early Onset Alzheimer’s Disease in Families with Genetic Mutations

    This study focuses on Alzheimer’s disease, particularly an early onset type caused by a genetic mutation inherited dominantly. Various therapies will be tested, including Gantenerumab, Solanezumab, Etalanetug, and Lecanemab. The purpose is to assess the safety, tolerability, and effectiveness of these treatments in slowing the progression or improving markers of the disease.

    The study targets individuals who either have a mutation causing Alzheimer’s disease or are at risk of having such a mutation. Participants can be without symptoms or have mild signs of dementia. Both actual medications and placebo will be used to compare the effectiveness of the treatments.

    Gantenerumab is administered subcutaneously (under the skin) every four weeks, while Solanezumab is given through intravenous (IV) infusion every four weeks. Etalanetug and Lecanemab are also administered intravenously. The study design includes different stages, where the participants and research staff may or may not know which specific treatment the participant is receiving, depending on the mutation and the drug being tested.

    This adaptive study aims to find effective treatments by testing multiple therapies. The study will analyze biomarkers (biological markers) from imaging and body fluids and assess clinical and cognitive outcomes to see if the treatments are working on a biological and clinical level. After the main treatment phase, there is an option for participants to receive the active drug in an open-label extension phase.

    • Etalanetug
    • Gantenerumab
    • Solanezumab
    • Lecanemab
  • Testing povetacicept for patients with lupus nephritis, IgA nephropathy, membranous nephropathy, or ANCA-associated vasculitis

    The clinical study focuses on patients with autoimmune kidney diseases, including immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. The study aims to determine if povetacicept (ALPN-303) is safe and potentially beneficial in treating these diseases.

    During the study, participants will receive povetacicept approximately every 4 weeks for 6 months. There is also the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. The study includes several dose levels of povetacicept, and participants will be assigned to either an 80mg or 240mg dose of the drug, administered by subcutaneous injection.

    The primary goal of the study is to assess the safety of povetacicept by monitoring the type, incidence, severity, and seriousness of any adverse events during and after the treatment period.

    • povetacicept

See more clinical trials in other cities in Spain: